Combined Effects of Fe3O4 Nanoparticles and Chemotherapeutic Agents on Prostate Cancer Cells In Vitro

Combined Effects of Fe3O4 Nanoparticles and Chemotherapeutic Agents on Prostate Cancer Cells In Vitro

Patients with metastatic castration-resistant prostate cancer (mCRPC) have poor outcomes. Docetaxel (DTX)-based therapy is a current standard treatment for patients with mCRPC. Approaches combining conventional chemotherapeutic agents and nanoparticles (NPs), particularly iron oxide NPs, may overcom...

Full description

Bibliographic Details
Main Authors:	Kanako Kojima, Sanai Takahashi, Shungo Saito, Yoshihiro Endo, Tadashi Nittami, Tadashige Nozaki, Ranbir Chander Sobti, Masatoshi Watanabe
Format:	Article
Language:	English
Published:	MDPI AG 2018-01-01
Series:	Applied Sciences
Subjects:	prostate cancer Fe3O4 nanoparticles carboplatin rapamycin reactive oxygen species
Online Access:	http://www.mdpi.com/2076-3417/8/1/134

Similar Items

Gas-blasting nanocapsules to accelerate carboplatin lysosome release and nucleus delivery for prostate cancer treatment
by: Shunli Fu, et al.
Published: (2021-03-01)

Blocking Mammalian Target of Rapamycin (mTOR) Alleviates Neuropathic Pain Induced by Chemotherapeutic Bortezomib
by: Zongsheng Duan, et al.
Published: (2018-07-01)

Rapamycin inhibits AR signaling pathway in prostate cancer by interacting with the FK1 domain of FKBP51
by: Jing Zhang, et al.
Published: (2020-09-01)

Sensitization of plasmid DNA to ionizing radiation by platinum chemotherapeutic drugs
by: Rezaee, Mohammad
Published: (2015)

The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment
by: Mark A. Eckert, et al.
Published: (2021-06-01)

Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics—A Review
by: Jelena S. Katanic Stankovic, et al.
Published: (2020-10-01)

Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer
by: Yuko Watanabe, et al.
Published: (2021-06-01)

Poorly Differentiated Small-Cell-Type Neuroendocrine Carcinoma of the Prostate: A Case Report and Literature Review
by: Kishore Kumar, et al.
Published: (2018-10-01)

Deprivation of arginine by recombinant human arginase in prostate cancer cells
by: Hsueh Eddy C, et al.
Published: (2012-04-01)

Role of Stromal Paracrine Signals in Proliferative Diseases of the Aging Human Prostate
by: Kenichiro Ishii, et al.
Published: (2018-04-01)

Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer
by: Hamid Attarian, et al.
Published: (2009-07-01)

Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study
by: Laura E. Barrett, et al.
Published: (2019-08-01)

THE DIFFERENCES OF APOPTOSIS EFFECTS BETWEEN COMBINATION OF MELOXICAM WITH GEMCITABINE-CARBOPLATIN CHEMOTHERAPY COMPARED TO GEMCITABINE-CARBOPLATIN CHEMOTHERAPY ALONE IN UROTHELIAL CARCINOMA CULTURE CELLS
by: Ananta Cahyo Nugroho, et al.
Published: (2019-01-01)

Carboplatin plus Paclitaxel in the First Line Therapy of Recurrent and Advances Endometrial Cancer
by: Hamid Attarian, et al.
Published: (2009-09-01)

Carboplatin hypersensitivity in children with glial tumors: a report of two cases
by: Tugce Kazgan, et al.
Published: (2016-12-01)

Evaluation of adjuvant chemotherapy in feline injection site-associated sarcoma
by: S.T. Pereira, et al.

Successful Chemotherapy with Carboplatin and S-1 for Thymic Carcinoma: A Case Report
by: Satoshi Igawa, et al.
Published: (2013-10-01)

Carboplatin Dosing for Adult Japanese Patients
by: HASEGAWA, YOSHINORI, et al.
Published: (2014)

Platinum derivatives: generic brands vs. original, in vitro tests
by: Cetean Sînziana, et al.
Published: (2015-12-01)

Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study
by: Shinogu Takashima, et al.
Published: (2020-10-01)

Quantitative [Fe]MRI of PSMA-targeted SPIONs specifically discriminates among prostate tumor cell types based on their PSMA expression levels
by: Sillerud LO
Published: (2016-01-01)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
by: Go Makimoto, et al.
Published: (2014-01-01)

A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss
by: Zin W. Myint, et al.
Published: (2021-09-01)

Successful Treatment with Taxane-Based Chemotherapy in Advanced Sebaceous Carcinoma: A Case Report and Literature Review
by: Shuji Ota, et al.
Published: (2019-01-01)

DIFFERENCES OF TUMOR MASSES AND HEMOGLOBIN LEVELS IN CERVICAL CANCER SQUAMOUS CELL TYPE PATIENTS TREATED WITH COMBINATION OF PACLITAXEL AND CARBOPLATIN CHEMOTHERAPY
by: R. Noviyani, et al.
Published: (2014-01-01)

Effects of Docetaxel Combined with Icotinib on Serum Tumor Markers and Quality of Life of Patients with Advanced Non-Small Cell Lung Cancer
by: Huawei LIN, et al.
Published: (2020-10-01)

Additional dexamethasone in chemotherapies with carboplatin and paclitaxel could reduce the impaired glycometabolism in rat models
by: Yanxiu Guo, et al.
Published: (2018-01-01)

Paclitaxel plus Carboplatin Chemotherapy for Primary Peritoneal Carcinoma: A Study of 22 Cases and Comparison with Stage III–IV Ovarian Serous Carcinoma
by: R. Kawaguchi, et al.
Published: (2012-04-01)

Syndrome of Inappropriate Secretion of Antidiuretic Hormone Caused by Carboplatin After Switching from Cisplatin in a Metastatic Urethral Cancer Patient
by: Yosuke Sugiyama, et al.
Published: (2017-05-01)

Carboplatin-Induced Bilateral Papilledema: A Case Report
by: N. Fischer, et al.
Published: (2009-04-01)

Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma
by: Timothy Budden, et al.
Published: (2018-01-01)

Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer
by: Zhang Y, et al.
Published: (2018-12-01)

Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer
by: Mohammad Mobayed, et al.
Published: (2009-11-01)

Effectiveness of treatment with endostatin in combination with emcitabine, carboplatin, and gemcitabine in patients with advanced non-small cell lung cancer: a retrospective study
by: Yu Xun, et al.
Published: (2018-04-01)

Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study
by: Hanneke N. G. Oude Elberink, et al.
Published: (2020-01-01)

Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials
by: Senri Yamamoto, et al.
Published: (2021-07-01)

Carboplatin Enhances the Activity of Human Transient Receptor Potential Ankyrin 1 through the Cyclic AMP-Protein Kinase A-A-Kinase Anchoring Protein (AKAP) Pathways
by: Kanako Miyano, et al.
Published: (2019-07-01)

Molecular Basis of Prostate Cancer and Natural Products as Potential Chemotherapeutic and Chemopreventive Agents
by: Bingke Bai, et al.
Published: (2021-09-01)

COMPARISON BETWEEN GEMCITABINE-CARBOPLATIN AND COMBINATION OF GEMCITABINE-CARBOPLATIN AND CELECOXIB IN UROTHELIAL CARCINOMA CELL APOPTOSIS
by: Widya Sakti Pratama, et al.
Published: (2019-01-01)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel: Two Case Reports
by: Tomoyuki Araya, et al.
Published: (2020-12-01)